Clinical trial
ACE Inhibitors, Angiotensin II Type-I Receptor Blockers and Severity of COVID-19
NCT04318418 is registered in ClinicalTrials.gov with Neuromed IRCCS as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- ACE Inhibitors, Angiotensin II Type-I Receptor Blockers and Severity of COVID-19
- Lead sponsor
- Neuromed IRCCS
- Phase
- Observational
- Overall status
- Completed
- Start date
- March 23, 2020
- Completion date
- June 30, 2020
- Enrollment
- 3,400 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.